MAP3K5 and pulmonary arterial hypertension: Pharmacological inhibition of ASK1 has demonstrated efficacy in a number of pre-clinical PAH models42, but a phase 2 clinical trial (ClinicalTrials.gov Identifier: NCT02234141) failed to show clinical benefit.